全文获取类型
收费全文 | 2091篇 |
免费 | 202篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 75篇 |
妇产科学 | 43篇 |
基础医学 | 368篇 |
口腔科学 | 48篇 |
临床医学 | 160篇 |
内科学 | 478篇 |
皮肤病学 | 31篇 |
神经病学 | 109篇 |
特种医学 | 443篇 |
外科学 | 179篇 |
综合类 | 51篇 |
预防医学 | 68篇 |
眼科学 | 8篇 |
药学 | 85篇 |
1篇 | |
中国医学 | 4篇 |
肿瘤学 | 138篇 |
出版年
2021年 | 13篇 |
2020年 | 12篇 |
2018年 | 23篇 |
2017年 | 23篇 |
2016年 | 22篇 |
2015年 | 32篇 |
2014年 | 48篇 |
2013年 | 55篇 |
2012年 | 47篇 |
2011年 | 57篇 |
2010年 | 58篇 |
2009年 | 73篇 |
2008年 | 55篇 |
2007年 | 62篇 |
2006年 | 67篇 |
2005年 | 53篇 |
2004年 | 51篇 |
2003年 | 37篇 |
2002年 | 36篇 |
2001年 | 44篇 |
2000年 | 34篇 |
1999年 | 34篇 |
1998年 | 88篇 |
1997年 | 93篇 |
1996年 | 92篇 |
1995年 | 75篇 |
1994年 | 53篇 |
1993年 | 72篇 |
1992年 | 32篇 |
1991年 | 31篇 |
1990年 | 49篇 |
1989年 | 71篇 |
1988年 | 59篇 |
1987年 | 63篇 |
1986年 | 66篇 |
1985年 | 80篇 |
1984年 | 45篇 |
1983年 | 38篇 |
1982年 | 33篇 |
1981年 | 46篇 |
1980年 | 48篇 |
1979年 | 16篇 |
1978年 | 32篇 |
1977年 | 32篇 |
1976年 | 27篇 |
1975年 | 24篇 |
1973年 | 9篇 |
1972年 | 13篇 |
1971年 | 9篇 |
1969年 | 11篇 |
排序方式: 共有2298条查询结果,搜索用时 0 毫秒
81.
Simon S. Jameson James M. Mason Paul N. Baker David W. Elson David J. Deehan Mike R. Reed 《The Journal of arthroplasty》2014
Influence of BMI upon patient outcomes and complications following THA was examined across a national cohort of patients. Outcomes were compared by BMI groups (19.0–29.9 kg/m2 [reference], 30.0–34.9 kg/m2 [obese class I], 35.0 kg/m2+ [obese class II/III]), adjusted for case-mix differences. Obese class I patients had a significantly smaller improvement in OHS (18.9 versus 20.5, P < 0.001) and a greater risk of wound complications (odds ratio [OR] = 1.57, P = 0.006). For obese class II/III patients, there were significantly smaller improvements in OHS and EQ-5D index (P < 0.001), and greater risk of wound complications (P = 0.006), readmission (P = 0.001) and reoperation (P = 0.003). Large improvements in patient outcomes were seen irrespective of BMI, although improvements were marginally smaller and complication rates higher in obese patients. 相似文献
82.
Interleukin-4 (IL-4) is a potent mediator of growth and differentiation of cells of several hematopoietic lineages. Interleukin-5 (IL-5) is a lineage-specific hematopoietic growth factor that stimulates the production of eosinophils and eosinophil colonies from normal human bone marrow cells. By using somatic cell hybrids and in situ chromosomal hybridization, we localized the IL-4 and IL-5 genes to human chromosome 5 at bands q23-31, a chromosomal region that is frequently deleted [del(5q)] in patients with myeloid disorders. By in situ hybridization, the IL-4 and IL-5 genes were found to be deleted in the 5q- chromosome of four patients with refractory anemia (RA) or therapy-related acute nonlymphocytic leukemia (t-ANLL), who had a del(5q). Thus a small segment of chromosome 5 contains IL-4, IL-5, IL- 3, and GM-CSF as well as other genes such as CD14 and EGR1. Our findings that each of these genes was deleted in the 5q- chromosome suggest that loss of function of one or more of these genes may play an important role in the pathogenesis of hematologic disorders associated with a del(5q). 相似文献
83.
Dvorak AM; Tepper RI; Weller PF; Morgan ES; Estrella P; Monahan-Earley RA; Galli SJ 《Blood》1994,83(12):3600-3612
We used light and electron microscopy to analyze the eyelid inflammation that develops in transgenic mice that overexpress interleukin-4 (IL-4; Tepper et al, Cell 62:457, 1990). Analysis of alkaline Giemsa-stained plastic sections examined by light microscopy (Dvorak et al, J Exp Med 132:558, 1970), as well as by routine transmission electron microscopy, indicated that the mast cells in the inflammatory eyelid lesions were undergoing piecemeal degranulation, a form of secretion in which the cells' cytoplasmic granules exhibit characteristic morphologic changes that are thought to be associated with the prolonged, vesicle-mediated release of the granules' constituents. Moreover, by using a newly reported enzyme affinity-gold method, which stains histamine based on binding to diamine oxidase-gold (Dvorak et al, J Histochem Cytochem 41:787, 1993), we show that these activated mast cells had released much of their histamine content. The eyelid lesions also exhibited increased numbers of mast cells; interstitial fibrosis, particularly around cutaneous nerves and blood vessels; activated fibroblasts; focal axonal damage; venules with endothelial cells containing numerous vesiculo-vacuolar organelles; and infiltrates of neutrophils and eosinophils. Our findings illustrate that overexpression of the IL-4 gene in vivo can result in eyelid lesions associated with piecemeal degranulation of mast cells, as well as tissue fibrosis and a variety of other pathologic changes. These results also represent the first direct morphologic evidence for histamine secretion by mast cells in vivo. 相似文献
84.
Predictive factors for latency period and a prognostic model for survival in patients with therapy‐related acute myeloid leukemia 下载免费PDF全文
Moshe C. Ornstein Sudipto Mukherjee Sanjay Mohan Paul Elson Ramon V. Tiu Yogenthiran Saunthararajah Cassie Kendeigh Anjali Advani Matt Kalaycio Jaroslaw P. Maciejewski Mikkael A. Sekeres 《American journal of hematology》2014,89(2):168-173
Therapy‐related acute myeloid leukemia (t‐AML) is an increasingly recognized sequela in patients receiving chemotherapy or radiotherapy for a primary malignancy or autoimmune disease. This study assessed factors related to the latency period (LP) between the antecedent disorder (AD) and t‐AML diagnosis and developed a comprehensive prognostic model to predict overall survival (OS). We evaluated a cohort of newly diagnosed t‐AML patients treated with cytarabine‐based induction therapy from 2001 to 2011. Multivariable linear and proportional hazards models were used to assess the impact of different classes of chemotherapy on the LP and to identify independent prognostic factors for OS. Of 730 treated AML patients, 58 (7.9%) had t‐AML. Median LP to t‐AML was 5.6 years (range, 0.5–38.4). 64% of patients achieved CR and median OS was 10.7 months. Independent prognostic factors of short LP were age at AD (P < 0.0001) and prior treatment with mitotic inhibitors (P = 0.05). Unfavorable cytogenetics (P = 0.004), antecedent hematologic or autoimmune disease (P = 0.01), age >60 (P = 0.03), and platelet count <30,000 μL (P = 0.04) at the time of t‐AML diagnosis were prognostic for inferior OS. A prognostic model using these factors was developed that risk stratified t‐AML patients into two groups: favorable and unfavorable. Patients in the favorable group had a median OS of 37.6 months compared with 6.4 months in patients comprising the unfavorable group (P < 0.0001). Multicomponent prognostic models integrating disease or treatment‐related covariates can help better understand how t‐AML evolves; and can be clinically useful in risk stratifying t‐AML patients undergoing induction therapy. Am. J. Hematol. 89:168–173, 2014. © 2013 Wiley Periodicals, Inc. 相似文献
85.
86.
87.
88.
89.
Mekhail TM Kawanishi-Tabata R Tubbs R Novick A Elson P Ganapathi R Ganapathi M Bukowski R 《Urologic oncology》2003,21(6):424-430
Limited information is available on the correlation of telomerase activity and the clinical and pathological characteristics, in patients with renal cell carcinoma (RCC). Telomerase repeat amplification protocol (TRAP) was used to measure telomerase activity in frozen RCC specimens from partial/radical nephrectomies performed between 1987 and 1991. Presence of tumor tissue was verified by a pathologist using hematoxylin and eosin stained sections. RNA was measured to ensure the presence of intact protein necessary for telomerase expression. Data on demographics, tumor type, and stage at presentation, local recurrence, distant metastasis, disease-free survival (DFS), and overall survival (OS) was collected, and telomerase activity was correlated with each of these variables. Forty-nine of 67 patients (73%) were telomerase positive (+ve). Gender and stage were the only variables that appeared to be associated with telomerase positivity. Tumors were telomerase +ve in 12/21 females (57 %) vs. 37/46 males (80%) (P = 0.07). Tumors were telomerase +ve in 85% of Stage IV, 76% of Stage III, and 70% of Stage I/II patients (P = 0.12). Five-year survival was 0% for Stage IV, 57% for Stage III, and 77% for Stage I/II patients (P < 0.001), DFS 54% for stage III and 84% for Stage I/II patients (P = 0.05). Telomerase activity, however, was not related to survival in either univariate or multivariate analysis. In patients with telomerase +ve tumors 5-year survival was 55%, and with telomerase −ve tumors 58% (P = 0.56). Stage was the only variable associated with OS or DFS in clear cell RCC patients. In patients with advanced disease, there is a high incidence of telomerase positivity was found, within this limited sample, however, no correlation with survival was found. 相似文献
90.